AU2010340358B2 - Recombinant butyrylcholinesterases and truncates thereof - Google Patents

Recombinant butyrylcholinesterases and truncates thereof Download PDF

Info

Publication number
AU2010340358B2
AU2010340358B2 AU2010340358A AU2010340358A AU2010340358B2 AU 2010340358 B2 AU2010340358 B2 AU 2010340358B2 AU 2010340358 A AU2010340358 A AU 2010340358A AU 2010340358 A AU2010340358 A AU 2010340358A AU 2010340358 B2 AU2010340358 B2 AU 2010340358B2
Authority
AU
Australia
Prior art keywords
nucleic acid
bche
isolated nucleic
polypeptide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010340358A
Other languages
English (en)
Other versions
AU2010340358A1 (en
Inventor
Steven Danso
Edward Hausknecht
Kalvin Yim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altimmune Inc
Original Assignee
Pharmathene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmathene Inc filed Critical Pharmathene Inc
Publication of AU2010340358A1 publication Critical patent/AU2010340358A1/en
Application granted granted Critical
Publication of AU2010340358B2 publication Critical patent/AU2010340358B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2010340358A 2009-12-21 2010-12-21 Recombinant butyrylcholinesterases and truncates thereof Ceased AU2010340358B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28444409P 2009-12-21 2009-12-21
US61/284,444 2009-12-21
PCT/US2010/003225 WO2011084145A2 (en) 2009-12-21 2010-12-21 Recombinant butyrylcholinesterases and truncates thereof

Publications (2)

Publication Number Publication Date
AU2010340358A1 AU2010340358A1 (en) 2012-07-19
AU2010340358B2 true AU2010340358B2 (en) 2014-07-24

Family

ID=44306009

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010340358A Ceased AU2010340358B2 (en) 2009-12-21 2010-12-21 Recombinant butyrylcholinesterases and truncates thereof

Country Status (6)

Country Link
US (2) US8729245B2 (enExample)
EP (1) EP2516664B1 (enExample)
JP (1) JP2013526840A (enExample)
AU (1) AU2010340358B2 (enExample)
CA (1) CA2784861A1 (enExample)
WO (1) WO2011084145A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010340358B2 (en) 2009-12-21 2014-07-24 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
US9688970B2 (en) 2013-10-01 2017-06-27 Kentucky Bioprocessing, Inc. Plant-based recombinant butyrylcholinesterase production methods
EA034022B1 (ru) * 2015-04-24 2019-12-19 Ферринг Б.В. Способ получения гонадотропина
PE20181156A1 (es) * 2015-11-05 2018-07-19 Bamboo Therapeutics Inc Genes de ataxia de friedreich modificados y vectores para terapia genica
CN108486114A (zh) * 2018-04-18 2018-09-04 西南大学 实现两个基因等量表达的基因元件及表达载体
EP3964265A1 (en) * 2020-09-07 2022-03-09 Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007040568A2 (en) * 2004-12-01 2007-04-12 Arizona Board Of Regents, Acting For And On Behalf Of Arizona State Univeristy Production and use of human butyrylcholinesterase
US20080213281A1 (en) * 2002-12-04 2008-09-04 Applied Molecular Evolution, Inc. C/O Eli Lilly And Company Patent Division Butyrylcholinesterase Variants that Alter the Activity of Chemotherapeutic Agents

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US6727405B1 (en) 1986-04-09 2004-04-27 Genzyme Corporation Transgenic animals secreting desired proteins into milk
US5215909A (en) 1986-06-18 1993-06-01 Yeda Research & Development Co., Ltd. Human cholinesterase genes
US5366894A (en) 1986-06-30 1994-11-22 Pharmaceutical Proteins Limited Peptide production
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
IL89703A (en) 1989-03-21 2001-10-31 Yissum Res Dev Co Polynucleotide encoding human acetylcholinesterase, vectors comprising said polynucleotide, cells transformed by said vectors, enzyme produced by said transformed cell, and uses thereof
US5227301A (en) 1989-11-03 1993-07-13 The 501 Institution For The Advancement Of Learning (Mcgill University) Immortalized bovine mannary epithelial cell line
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5831141A (en) 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
IL101600A (en) 1992-04-15 2000-02-29 Yissum Res Dev Co Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them
US6110742A (en) 1992-04-15 2000-08-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Synthetic antisense oligodeoxynucleotides targeted to AChE
ES2146648T3 (es) 1993-03-09 2000-08-16 Genzyme Corp Procedimiento de aislamiento de proteinas de la leche.
US5610053A (en) 1993-04-07 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells
DE4326665C2 (de) 1993-08-09 1995-07-13 Biotest Pharma Gmbh Verfahren zur Sterilfiltration von Milch
US6025183A (en) 1994-02-28 2000-02-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Transgenic animal assay system for anti-cholinesterase substances
US5932780A (en) 1994-02-28 1999-08-03 Yissum Research Development Company Of Hebrew University Of Jerusalem Transgenic non-human animal assay system for anti-cholinesterase substances
US6204431B1 (en) 1994-03-09 2001-03-20 Abbott Laboratories Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk
US5807671A (en) 1995-01-09 1998-09-15 Yissum Research Development Company Of Hebrew University Of Jerusalem Method of screening for genetic predisposition to anticholinesterase therapy
US5780009A (en) 1995-01-20 1998-07-14 Nexia Biotechnologies, Inc. Direct gene transfer into the ruminant mammary gland
US6001625A (en) 1995-05-19 1999-12-14 The United States Of America As Represented By The Secretary Of The Army Site-directed mutagenesis of esterases
IL115873A0 (en) 1995-11-03 1996-01-31 Peri Dev Applic 1985 Ltd Transgenic protein production
US6326139B1 (en) 1996-01-11 2001-12-04 Yissum Research Development Company Of Hebrew University Of Jerusalem Method of screening for genetic predisposition to anticholinesterase therapy
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
US20020184655A1 (en) 1997-12-01 2002-12-05 Henryk Lubon Methods for the degradation and detoxification of organic material using urine produced by transgenic animals and related transgenic animals and proteins
US7157615B2 (en) 1998-03-17 2007-01-02 Nexia Biotechnologies, Inc. Production of biofilaments in transgenic animals
EP1329513B1 (en) 1998-08-25 2011-12-07 University of Washington Rapid quantitative analysis of proteins or protein function in complex mixtures
JP2002525047A (ja) 1998-09-16 2002-08-13 ネクシア バイオテクノロジーズ， インコーポレイテッド 尿における組換え蛋白質の産生
US6580017B1 (en) 1998-11-02 2003-06-17 Genzyme Transgenics Corporation Methods of reconstructed goat embryo transfer
AU1621900A (en) 1998-11-13 2000-06-05 New York University Transgenic animals as urinary bioreactors for the production of protein in the urine, recombinant dna construct for kidney-specific expression, and method of using same
EP1148779B1 (en) 1999-01-06 2007-12-12 Merrimack Pharmaceuticals, Inc. Expression of secreted human alpha-fetoprotein in transgenic animals
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
ES2209915T3 (es) 1999-04-26 2004-07-01 U.S. Army Medical Research And Materiel Command Esponjas de destoxificacion op de actuacion diferencial.
IL131707A0 (en) 1999-05-31 2001-03-19 Yissum Res Dev Co Acetylcholinesterase-derived peptides and uses thereof
WO2001071014A2 (en) 2000-03-17 2001-09-27 Boyce Thompson Institute For Plant Research, Inc. Expression of recombinant human acetylcholinesterase in transgenic plants
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
US7070973B2 (en) 2000-12-26 2006-07-04 Board Of Regents Of The University Of Nebraska Butyrylcholinesterase variants and methods of use
IL142875A (en) 2001-04-30 2009-08-03 Avigdor Shafferman PEG-linked cholinesterases for the detoxification of circulating organophosphorus
CA2447236A1 (en) 2001-05-21 2002-11-28 Nektar Therapeutics Pulmonary administration of chemically modified insulin
CN1880457B (zh) * 2001-10-11 2010-05-26 麦克公司 Ad6重组核酸
AU2002365202A1 (en) 2001-11-09 2003-09-02 Entremed, Inc. Synthetic genes for malarial proteins and methods of use
WO2003054182A2 (en) 2001-12-21 2003-07-03 Nexia Biotechnologies, Inc. Production of butyrylcholinesterases in transgenic mammals
EP1670950A2 (en) 2003-10-10 2006-06-21 Yissum Research Development Company, of The Hebrew University of Jerusalem Method and kit for assessing anxiety or disposition thereto in a subject
EP2053409A1 (en) * 2003-11-20 2009-04-29 F. Hoffmann-La Roche Ag Specific markers for metabolic syndrome
US20090169520A1 (en) 2004-01-09 2009-07-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds, Pharmaceutical Compositions and Therapeutic Methods of Preventing and Treating Diseases and Disorders Associated With Amyloid Fibril Formation
WO2007011390A2 (en) 2004-10-09 2007-01-25 Government Of The United States As Represented By The Secretary Of The Army Large-scale production of human serum butyrylcholinesterase as a bioscavenger
WO2006063055A2 (en) 2004-12-06 2006-06-15 Bolder Biotechnology, Inc. Enzyme conjugates for use as detoxifying agents
IL169377A (en) 2005-06-23 2012-09-24 Avigdor Shafferman Uniformly conjugated serine hydrolases
ES2534282T3 (es) * 2006-06-29 2015-04-21 Dsm Ip Assets B.V. Un método para lograr la expresión polipeptídica mejorada
WO2008019036A2 (en) 2006-08-04 2008-02-14 Pharmathene Inc. Long half-life recombinant butyrylcholinesterase
EP2185591B1 (en) * 2007-08-20 2014-05-14 Glaxo Group Limited Production method
US7846428B2 (en) * 2007-10-05 2010-12-07 Merial Limited Articular cartilage gene therapy with recombinant vector encoding BMP-7
AU2010340358B2 (en) 2009-12-21 2014-07-24 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213281A1 (en) * 2002-12-04 2008-09-04 Applied Molecular Evolution, Inc. C/O Eli Lilly And Company Patent Division Butyrylcholinesterase Variants that Alter the Activity of Chemotherapeutic Agents
WO2007040568A2 (en) * 2004-12-01 2007-04-12 Arizona Board Of Regents, Acting For And On Behalf Of Arizona State Univeristy Production and use of human butyrylcholinesterase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Raymond et al, 2007, PloS ONE, vol 2, e152 *
Robinson et al, 2008, PLoS ONE, vol 3, e1801 *

Also Published As

Publication number Publication date
US8952143B2 (en) 2015-02-10
EP2516664A1 (en) 2012-10-31
US8729245B2 (en) 2014-05-20
EP2516664B1 (en) 2015-07-22
WO2011084145A2 (en) 2011-07-14
JP2013526840A (ja) 2013-06-27
WO2011084145A3 (en) 2013-05-30
US20140220658A1 (en) 2014-08-07
AU2010340358A1 (en) 2012-07-19
US20120252094A1 (en) 2012-10-04
EP2516664A4 (en) 2013-11-13
CA2784861A1 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
US8952143B2 (en) Recombinant butyrylcholinesterases and truncates thereof
McBlane et al. Cleavage at a V (D) J recombination signal requires only RAG1 and RAG2 proteins and occurs in two steps
EP2539445B1 (en) Use of endonucleases for inserting transgenes into safe harbor loci
AU2017201235B2 (en) Compositions and methods for the treatment of hemoglobinopathies
JP6392263B2 (ja) ホスホ−６−マンノースへのマンノース−１−ホスホ−６−マンノース結合の加水分解
KR102733409B1 (ko) Rna-가이드 유전자 편집 및 유전자 조절
KR20210125560A (ko) 유전성 질환의 치료를 위한 것을 포함하는, 아데노신 데아미나제 염기 편집기를 사용한 질환-관련 유전자의 스플라이스 수용체 부위 파괴
US20240279630A1 (en) Isolated cas13 protein and use thereof
JP2022097653A (ja) ヒトα－ガラクトシダーゼバリアント
EP2910632B1 (en) Highly functional enzyme having modified substrate specificity of human beta-hexosaminidase b and exhibiting protease resistance
KR20160050069A (ko) Cas9 변이체 및 그의 용도
JPS6084299A (ja) ヒト神経成長因子の遺伝子組換えによる調製法
US20090217400A1 (en) Enzymes, cells and methods for site specific recombination at asymmetric sites
KR20170120126A (ko) 숙주 세포 단백질 변형
US20240307558A1 (en) Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of KRT5, KRT14, LAMB3, and COL7A1 genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-KRT5, or Escherichia coli strain SCS110-AF/VTvaf17-KRT14, or Escherichia coli strain SCS110-AF/VTvaf17-LAMB3, or Escherichia coli strain SCS110-AF/VTvaf17-COL7A1 carrying the gene therapy DNA vector, m
Ceylan et al. Cloning, expression, and characterization of human brain acetylcholinesterase in Escherichia coli using a SUMO fusion tag
KR20220106738A (ko) 조작된 리파제 변이체
US5248604A (en) Enzymatically active recombinant human acetylcholinesterase and hosts and vectors for expression thereof
EP4735591A2 (en) Engineered acid alpha-glucosidase variants
US8318155B2 (en) Nucleic acid cleaving agent
JP5013375B2 (ja) メッセンジャーｒｎａ干渉酵素が促進する生細胞における単一タンパク質産生
EP3473709B1 (en) Dna vector containing a gene encoding an equine butyrylcholinesterase, for transformation and integration into leishmania tarentolae chromosome.
WO1993001830A1 (en) Expression of enzymatically active recombinant human acetylcholinesterase and uses thereof
RU2732795C1 (ru) Рекомбинантный слитый белок
US20090311743A1 (en) Process for the Production, in Prokaryotes, of Active, Stable Transposases of Mariner Mobile Genetic Elements

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired